Aktie 254463 SYNTARA LIMITED
Zu einer Liste hinzufügen
Um diese Funktionalität nutzen zu können, müssen Sie Mitglied sein
EinloggenRegistrieren

Andere Sprachen Syntara Limited

Aktien

254463

AU0000312480

SNT

Schlusskurs Australian S.E.
Andere Börsenplätze
 00:00:00 30.04.2024 		% 5 Tage % 1. Jan.
0,016 AUD +6,67 % Intraday Chart für Syntara Limited -5,88 % -20,00 %
30.04. Transcript : Syntara Limited, Q3 2024 Earnings Call, Apr 30, 2024
29.02. Syntara Limited meldet Ergebnis für das am 31. Dezember 2023 endende Halbjahr CI

Andere Sprachen

Suchen
Ergebnisse ansehen
Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!
100% kostenlose Registrierung
Syntara Reaches 50% Recruitment in Phase 2 Trial for Bone Marrow Cancer Treatment
Syntara Limited Reports Earnings Results for the Half Year Ended December 31, 2023
Syntara to Begin Phase Two Study for SNT-5505 Combination Therapy Later in 2024 After Government Grant
Syntara Opens Up to AU$2 Million Share Purchase Plan
Syntara Starts Dosing Patients in Phase Two Trial of Drug Candidate
Syntara Receives AU$5.2 Million R&D Tax Rebate
Pharmaxis Doses First Patient in Phase Two Sleep Trial
University of Birmingham : Promising target for liver disease treatments identified; Inhibiting a protein involved in liver inflammation has the potential to reduce or stop fibrosis in patients with non-alcoholic steatohepatitis, trial finds
Pharmaxis Ltd Reports Earnings Results for the First Quarter Ended September 30, 2023
Pharmaxis Sells Mannitol Business; Shares Fall 3%
Arna Pharma Pty Ltd completed the acquisition of Mannitol respiratory business of Pharmaxis.
BTC Health Arm to Continue Distributing Bronchitol, Aridol in Australia
Pharmaxis to focus on clinical-stage drug development
Pharmaxis to Change Name Amid Restructure, Appoints Chair
Arna Pharma Pty Ltd entered into definitive agreement to acquire Mannitol respiratory business of Pharmaxis.
Australian Bourse Halts Trading in Pharmaxis’ Securities
Pharmaxis Ltd Reports Earnings Results for the Full Year Ended June 30, 2023
Pharmaxis Secures $4 Million R&D Loan
Pharmaxis says majority of patients in fibrosis trial see significant improvement
Pharmaxis Logs Positive Results in Cancer Trial
Keine Ergebnisse zu dieser Suche
Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Filter

Suchen

Datum der Veröffentlichung

Vom

Bis

  1. Börse
  2. Aktien
  3. 254463 Aktie
  4. Nachrichten Syntara Limited
  5. Andere Sprachen